Introduction
The Japan Society of Interventional Radiology (JSIR) is involved in developing and encouraging the widespread use of interventional radiological (IR) treatments in Japan. Accordingly, the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (CGJSIR) was established in May 2009 and began to devise practical guidelines for the standardization of IR treatments in Japan. Among the various IR treatments, vascular embolization is performed most often. It is used to control tumors, stop acute hemorrhaging in emergency medical care, and manage other conditions and diseases. Various materials such as metallic coils, gelatin sponges, cyanoacrylates, and ethanol have been employed for vascular embolization. However, apart from metallic coils and some gelatin sponge products, no other embolic materials have been approved for intravascular use. Since n-butyl cyanoacrylate (NBCA) and other embolic materials are considered to be necessary for certain vascular procedures even though they are not approved for vascular use, they are used under the supervision of interventional radiologists. Histoacryl (B. Braun Aesculap, Tokyo, Japan) is an NBCA product that is commercially available in Japan. In April 2008, the JSIR produced 'a statement regarding the embolic materials required for special vascular care', which refers to their indications, usage, and complications [1] . In October 2010, the CGJSIR formed the Practice Guidelines for the Use of Embolic Materials Required for Special Vascular Care Committee (PGERSCC) in order to devise guidelines for the use of gelatin sponge, NBCA, and ethanol because they have been found to be extremely useful in clinical practice, even though they have not been approved for vascular use. The Panel of Practice Guidelines for the Use of NBCA in Embolotherapy (PGNBCA panel) and the Review Board of Practice Guidelines for the Use of NBCA in Embolotherapy (RBNBCA) have since been launched by the PGERSCC. In the present article, the authors describe the current consensus regarding the use of NBCA for vascular embolization in Japan, and critically evaluate associated experimental and clinical reports.
Purpose
The purpose of the guidelines outlined below is to describe the current consensus regarding, and appropriate practical procedures for, transcatheter vascular embolization using NBCA. The guidelines devised by the CGJSIR aim to facilitate decision-making regarding IR treatments in clinical practice. Thus, they aim to be practical or technical in nature and to supplement the guidelines devised by other medical societies dealing with specific diseases or organs. Hopefully, the guidelines will ensure that transcatheter vascular embolization using NBCA is performed in an appropriate and safe manner and improve the relationships between medical staff and their patients. Furthermore, the guidelines should make it easier for operators to perform vascular embolization using NBCA. It should be noted that whilst the administrative board and guidelines committee of the JSIR have responsibility for producing the guidelines, operators are responsible for their application and should always take the patient's condition and the institutional situation into account. As a general rule, these guidelines are based on scientific evidence. When insufficient evidence was available for a particular recommendation, the recommendation was graded using a previously described classification system (see the ''Recommendations and comments'' section), and comments outlining the rationale for the recommendation in more detail have been added. Many kinds of materials are used for transcatheter vascular embolization. Operators should choose the most appropriate embolic materials based on the patient's situation and the clinical conditions. NBCA can be employed for vascular embolization; however, its usage has not been standardized. These guidelines represent the current consensus and are not intended to be used as a strict set of instructions that would limit doctors' decision-making power; i.e., the final clinical decision is left to the discretion of the treating physician.
because most previous reports about the topic were case reports or described case series. The literature was reviewed by searching the PubMed database using keywords based on the PECO (patient, exposure, comparison, and outcome) parameters. First, 368 studies were obtained using the following keywords: reports were collected through an exhaustive manual search using ''N-butyl cyanoacrylate AND embolization'' as keywords; however, non-complications-related case reports involving B 2 cases were excluded. As a result, the remaining 78 reports were included. Finally, we adopted 181 papers from among these 446 reports, after excluding 265 papers on cyanoacrylates other than NBCA or endoscopic or direct injection-based treatments (Fig. 1 ).
Structured abstracts and evidence level setting
The panel and collaborative members critically reviewed the 181 abovementioned publications and created structured abstracts for them. In order to avoid bias in the interpretation of the papers or simple misreading, the structured abstracts were peer reviewed by another member of the committee. With respect to the examined papers, we classified the level of evidence provided in each paper according to the taxonomic system for structured abstracts produced by the Minds medical literature evaluation committee (Table 1) [2] .
Recommendations and comments
We have provided answers to each CQ and added comments from the guidelines committee regarding the use of NBCA for vascular embolization. The council of the PGNBCA panel has also graded each recommendation according to the classification system described in Table 2 . This classification system was also used to grade the recommendations provided in the stroke treatment guidelines developed by the Japan Stroke Society (2009 edition) [3] . In cases in which a recommendation was based on limited scientific evidence, the associated treatment was classified as ''a treatment that might be considered,''which is used in the abovementioned stroke treatment guidelines, rather than ''a treatment that is encouraged,''which is described in the Minds recommendation grading system, in consideration of the fact that the intravascular administration of NBCA is contraindicated at present. In addition, recommendation grades are not provided for the responses to the CQ about the effects or mechanism of action of NBCA or those to the CQ about NBCA's complications, but the information provided in these responses is important, as it helps operators to understand the properties of NBCA before using it for vascular embolization. NBCA is used for vascular embolization at the discretion of operators. In line with this, CQ were selected with a view to enabling interventional radiologists to access information regarding treatment outcomes and complications, which are needed to examine the applicability of vascular embolization with NBCA, or information regarding necessary or safe treatment techniques. At present, there is insufficient information about vascular embolization using NBCA because it can be used to treat a heterogeneous range of diseases, and vascular embolization is often performed in the emergency setting. Therefore, the recommendation grades were determined after discussing the most important issues in the medical setting and obtaining the PGNBCA panel's consensus. Accordingly, the recommendation grades are not always consistent with the level of evidence that supports them. It is necessary for physicians to explain appropriate alternative treatment choices to patients and their families if they do not agree with the recommended methods. Physicians should consult interventional radiologists or transport candidates for vascular embolization using NBCA to another facility when it cannot be performed at their own facility. Providing the abovementioned approach is adhered to, alternative treatments are acceptable.
The comments included in the general descriptions are intended to make it easier for operators to understand the issues associated with each CQ. They should be regarded as references that facilitate the examination of CQ-related problems. The specific comments about each CQ were critically appraised by all of the authors before being finally approved via consensual decision making. These guidelines are subject to revision whenever new evidence arises, new treatment methods are established, or social conditions change. Please contact the JSIR Office if you wish to propose CQ for inclusion in the guidelines, or have written or read articles that the JSIR members and/or guideline users might find useful. These guidelines were first published on the website of the JSIR in December 2012 (http://www.jsivr.jp/guideline/guidelineNBCA.html).
General comments

Cyanoacrylates
Cyanoacrylates (CA) are instantaneous adhesives that have been used around the world in the industrial, domestic, and medical settings since 1957. CA-based glues instantaneously adhere firmly to most kinds of material at room temperature and have been used in various fields. The polymerization of CA, which is induced when they come into contact with a trace amount of water or an anion, causes them to harden and become adhesive; however, they form low viscosity liquids in the monomer state (Fig. 2) [4, 5] .
CA polymers are hard and fragile. Whilst they exhibit high levels of shear strength, they are vulnerable to various types of stress, such as peeling and shock trauma. Some CA agents have had their curing strength increased by Cyanoacrylates for medical use
In the surgical field, CA are used to close wounds and induce hemostasis. Octyl and butyl CA are suitable for use in biological organisms because of their characteristics; i.e., they are elastic, odorless, and non-toxic after polymerization. They possess large alkyl groups, and hence, are chemically stable. NBCA, which is classified as both a butyl CA and an iso-butyl CA (IBCA), is used around the world as a medical superglue. On the other hand, ethyl CA and methyl CA have been used for medical purposes in the past, but are not used at present because their methyl/ethyl groups are very small; therefore, methyl CA and ethyl CA can easily decompose into toxic formaldehyde and alkyl cyanoacetate. However, the cyano groups of CA, which are chemically stable, do not generate toxic cyanide-based substances, e.g., hydrocyanic acid (HCN). Octyl CA is used to close wounds affecting the gums and repair the cornea, since it also has bactericidal and hemostatic effects.
Bacterial genome experiments have demonstrated that NBCA and IBCA are mutagenic; however, they have not been proven to be carcinogenic [6] . NBCA is applied to skin wounds to achieve hemostasis. The blue type (Histoacryl blue), which contains dye (D&C Violet No. 2), and the colorless type, which does not, are commercially available in Japan.
History and current status of intravascular treatment using NBCA NBCA has been used in endoscopic sclerotherapy for esophageal varices and has come to be used in the treatment of bleeding disorders and arteriovenous malformations (AVM), in which the liquid is mixed with an oily contrast medium that is mainly composed of the ethyl ester of iodinated poppy-seed oil fatty acids (Lipiodol, Guerbet Japan, Tokyo, Japan) and injected into blood vessels.
In the cerebrovascular field, evidence supporting the use of NBCA has been provided by a number of clinical trials. Regarding clinical practice guidelines, NBCA-based sclerotherapy for esophageal and gastric varices has been recommended in the United States and the EU, and it is also highly recommended by level 2 evidence in Japan [7] . In the United States, it is recommended that vascular embolization should be employed before surgical resection or preoperative stereotactic radiotherapy, and it has also been recommended as a treatment for focally symptomatic or intractable infarction. In Japan, a combination of vascular embolization and surgery has been recommended for grade 3 (according to the Spetzler-Martin classification) cerebral AVM [3] . As for conditions affecting the thoracoabdominal or other regions, vascular embolization is used in the clinical setting on a daily basis in Japan and other countries, based on the findings of a number of research reports.
Pharmaceutical and legal issues
In Japan, the pharmaceutical law classifies NBCA under ''orthopedic medical devices-4'' as a wound dressing material for skin defects. Thus, NBCA is only approved for treating skin damage, and its intravascular administration is contraindicated. Therefore, at present, the intravascular administration of NBCA is considered to be off-label use and can only be performed at the discretion of physicians. The JSIR recommendations have been developed because whilst there are no clear legal criteria that can be used to assess the appropriateness of the off-label use of drugs and medical devices, it is considered that there is increasing clinical need for vascular embolization using NBCA [1] . Regarding drug usage and the predictability of side effects, a Japanese Supreme Court ruling called for strict compliance with the instructions listed in drug package inserts (ruling January 23, 1996) [8] . So, operators should take great care regarding the usage of medical devices and drugs. We should also highlight that the side effects relief (compensation) system that operates in Japan does not apply to health hazards that occur during the use of a treatment that is not described in a drug's package insert; therefore, sufficient consent should be obtained from the patient before treatment, particularly when complications are expected.
International situation
A product containing NBCA and contrast material (iodized poppy seed oil fatty acid ethyl ester and tantalum powder) that is used for embolizing cerebral AVM in the preoperative setting was approved for use in the United States in 2000 and has since been used in more than 10,000 cases. In addition, NBCA is licensed as an embolic material for use during endoscopic sclerotherapy for esophageal and gastric varices in Korea, the EU, Australia, Mexico, Uruguay, Morocco, and Turkey, but in Japan it was only approved for gastric variceal sclerotherapy in May 2013. Vascular embolization using NBCA has not been officially approved for use in other treatments, although a number of clinical reports about the use of NBCA during such treatments have been published in other countries [9] .
Rationale for performing vascular embolization using NBCA CQ1 By what mechanism does NBCA embolize vessels?
Recommendation After coming into contact with blood plasma, NBCA starts to polymerize. As a result, blood vessels that are subjected to NBCA injection are embolized via three mechanisms: (1) cast and thrombus formation, (2) the adhesion of NBCA to the inner vascular wall, and (3) damage to the vascular endothelium.
Specific comments NBCA polymerizes after coming into contact with ionic media in the blood via the following three mechanisms [17, 54, 58, 59, 64, 94, 95, 97, 103, 123, 130, 135, 139, 161] :
(1) Cast and thrombus formation: NBCA polymerizes to form a solid material or cast, which adjusts to the shape of the target vessel [103] . The cast fills the vascular lumen, thereby preventing blood from flowing through it [30, [102] [103] [104] 117] . As a result, the vessel becomes thrombosed. It takes just 0.087 s for a cast to form after NBCA comes into contact with blood plasma [132] . (2) Adhesion to the vascular wall: after being injected, the NBCA near to the tip of the catheter becomes hard and simultaneously adheres to the vascular wall. An in vitro study measuring the bonding strength achieved between the common carotid artery of a Japanese domestic white rabbit and a microcatheter after the injection of 50 ll of NBCA (without any additives) found that NBCA exhibited a very strong adhesive force (7 kgf) [132] . In clinical use, NBCA is mixed with Lipiodol to adjust its polymerization time. A pathological evaluation of a mixture of NBCA and Lipiodol revealed that Lipiodol localizes in the central regions of blood vessels, whereas NBCA is deposited in the peripheral regions of blood vessels [24, 154] . (3 Specific comments NBCA is indicated for various conditions, including vascular conditions (aneurysms and malformations), bleeding (iatrogenic damage, trauma, and inflammation), tumors, and venous disease (varices and portal vein system disease), regardless of the location of the target lesion.
There have been many reports about the use of NBCA for treating cerebral vascular malformations, and some prospective studies have examined its use for preoperative vascular embolization [10, 38, 52, 53, 55, 57, 63, 86, 92, 94, 96, 100] . In addition, other applications, including the use of NBCA to treat spinal vascular disease and during embolization for endoleaks that develop after endovascular aneurysm repair, have been described in recent studies [22, 34, 35, 40, 83, 108, 129, 146, 149, 152, 167] .
NBCA is also used to induce embolization in cases involving bleeding caused by iatrogenic damage or trauma [25, 39, 70, 75, 78, 116, 117] . In particular, NBCA is a useful embolic material in the following situations: (a) cases in which pseudoaneurysms cannot be embolized via selective catheterization using the isolation technique; (b) embolization involving the preservation of the parent artery [56, 134, 149, 163, 167, 174, 183] ; (c) cases in which coil embolization might be unsuitable because of the condition of the target vessels, e.g., those involving markedly tortuous, stenotic, or fine vessels [54, 72, 87, 135, 138, 165] ; (d) cases involving patients in a hypocoagulable state (refer to CQ6). Furthermore, vascular embolization with NBCA has also been reported to be useful for nasal bleeding [103, 104] , hemoptysis [16, 141] , and gastrointestinal bleeding.
In cancer patients, NBCA is indicated for tumor bleeding [72] and can also be used to achieve a palliative therapeutic effect by improving the tumor response [32, 41, 142, 145, 176] . In addition, NBCA has been indicated for arterial redistribution and hepatic arterial catheter fixation during hepatic arterial infusion chemotherapy [68, 159, 180, 181] . In the venous system, retrospective studies examining the use of NBCA for percutaneous transhepatic portal venous embolization have also been reported [19, 45, 48, 49, 77] , and there have been several studies about the use of NBCA for pelvic congestion syndrome and varicoceles [27, 65, 109, 157] .
Complications and safety management CQ3 What complications are associated with vascular embolization using NBCA?
Recommendation The complications associated with NBCA use are classified into the following five types: (1) tissue ischemia caused by vascular embolization, (2) hemorrhaging caused by increased pressure in the AVM nidus, (3) systemic and/ or local reactions, (4) catheter adhesion to the vascular wall, and (5) other rare but important complications.
Specific comments
(1) Tissue ischemia (Table 4) Even if the target embolization range can be controlled as intended, ischemia can develop in the perfused region, depending on the collateral vessels. Moreover, it is often difficult to control the embolization range during vascular embolization using NBCA, which can cause non-target embolization. In particular, vascular embolization using NBCA can result in the undesirable distal spread of NBCA; NBCA reflux [16, 39, 99, 101, 102, 105, 116, 117, 136, 141, 144, 145, 161] ; a small amount of NBCA becoming attached to the catheter tip, causing it to be released into non-target vessels during catheter removal 10; and the induction of vital organ ischemia through collateral channels. Regarding the distal spread of NBCA, venous outflow has been detected in cases involving high-flow AVM/fistulas [18, 30, 76, 82, 137] . The NBCA injected into small and slow-flowing vessels can easily reflux around the catheter tip, which can result in the NBCA becoming attached to the catheter tip and the subsequent spread of the adhesive into the parent arteries. As for vital organ ischemia induced via collateral channels, unintended embolization of the anterior spinal artery by NBCA after its migration through the intercostal and lumber arteries has been reported [110, 144] .
The following complications of NBCA have also been reported: brain infarcts [10, 29, 42 (Table 5) Infections [43] , brain abscesses [31] , liver abscesses [19, 182] , acute pancreatitis [162] , thrombophlebitis [157] , and portal thrombosis [48] have also been reported as complications associated with NBCA use.
CQ4 How should NBCA be used to safely embolize vessels?
Recommendations There are various technical aspects to performing vascular embolization using NBCA safely, so the procedure should be carried out by, or with the assistance of, experienced interventional radiologists.
Operators should understand the characteristics of the target vessels prior to NBCA injection. In addition, NBCA should be mixed with contrast material to make it radiopaque, and it should be administered under X-ray fluoroscopy.
(1) The optimal volume, injection speed, and ratio of the NBCA-Lipiodol mixture should be determined to facilitate successful vascular embolization. Repeated contrast injection under fluoroscopy through properly placed catheters is helpful for evaluating hemodynamics, blood flow, and the diameter and volume of the target vessels [25, 47, 72, 80, 113, 123, 175] . NBCA is radiolucent, and therefore, is usually mixed with radiopaque materials such as Lipiodol [66, 91] . (2) Immediately before the injection of NBCA, the microcatheter should be thoroughly flushed with 5 % nonionic dextrose solution to completely remove any ionic solutions from its lumen [64, 75, 121, 130, 140, 176] . The simultaneous perfusion of 5 % dextrose through the guiding catheter during the injection of NBCA delays contact with ionic substances and prolongs the polymerization period of NBCA [123, 141] . (3) X-ray fluoroscopy, digital subtraction angiography, and biplanar road-mapping can be used to monitor procedures involving NBCA [46, 125, 161] . Operators should closely observe the progression of the NBCA during the procedure [16] , and high-resolution fluoroscopic monitoring equipment can be used for this purpose [91] . Monitoring by several doctors at the same time aids precise judgments during the procedure. (4) Several injection techniques have been reported. The continuous column method, in which the NBCA is injected slowly but continuously to allow it to form a cast inside the lumen, is the most common method and allows controlled NBCA delivery, which prevents reflux [16, 37, 46, 92, 98, 102, 137, 149] . In addition, intermittent injection with the aim of delivering drips of NBCA (the pumping method) and a method in which the NBCA in the catheter is pushed out with a bolus of dextrose (the sandwich technique) have also been reported [21, 46, 48, 141] . The injection should be stopped when blood flow arrests or undesirable migration of the NBCA into the distal portion of the target vessel, the spilling of NBCA along the catheter tip, severe symptoms, or other risky situations occur [13, 16, 134, 141] . (5) The catheter should be retracted immediately after the injection of NBCA to avoid inadvertent adherence to the surrounding vascular tissue [61, 116, 125, 130, 181] . Syringe aspiration is acceptable in order to induce negative pressure in the catheter to prevent NBCA migration during the removal of the catheter [46, 96] . A small amount of NBCA will remain inside the removed catheter after NBCA injection. Therefore, the successive usage of the same catheter could result in undesirable embolization. Hence, another catheter should be used for additional NBCA injections, particularly in the neurovascular field [72, 139] . Post-embolization angiography can be used to confirm the embolized region and the patency of the parent artery. Coaxial microcatheters are highly recommended for injecting NBCA because their guiding catheters preserve proximal vessels. The ability of flow-guided catheters to deliver NBCA to more distal locations would seem to be a potential safety advantage [10, 53] . (6) Super-selective embolization should be performed after the placement of a microcatheter near to the target lesion, in order to prevent the administration of an excess amount of NBCA [39, 103, 104] . Injecting small intermittent aliquots of NBCA rather than a single large bolus [71, 102] or the combined use of NBCA and other embolic materials is considered to be an effective technique for dose optimization [50, 134] . Blood flow control should be considered when NBCA migration is expected in high-flow lesions. Flow stagnation via the use of balloon catheters or wedge catheters, the combined use of vascular embolization and metallic coils or other materials, or temporary vasoconstriction via the local injection of diluted epinephrine, have been reported in such situations [15, 29, 30, 33, 42, 50, 72, 92, 105, 128, 137, 139, 152, 158, 187] . However, the injection of NBCA using balloon or wedge catheters can cause unexpected migration of the adhesive into a non-target area through vascular anastomoses that have not been detected on preoperative angiography, so these procedures should be carried out with great care. (7) NBCA has more immediate and permanent effects than gelatin sponge or metallic coils. Therefore, operators should take care to only embolize the target vessels [66] . It is difficult to apply vascular embolization using NBCA to the anterior spinal, mesenteric, or other vital arteries because excessive embolization of these arteries would cause severe neurological injuries and/or organ ischemia [47, 89] . The lidocaine provocation test, a neurological examination, is useful for preventing unexpected events after vascular embolization [47, 89] .
In summary, vascular embolization using NBCA should be carried out by, or under the guidance of, proficient doctors. NBCA should be administered under appropriate imaging guidance and should be mixed with contrast material to make it easier to visualize [16, 141] .
CQ5 How should patients' pain be managed during vascular embolization using NBCA?
Recommendation In general, no specific pain management strategy is required. However, in some cases it might be necessary to administer pain control drugs, such as opioid analgesics, non-pyrazolone analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), or epidural anesthesia.
Specific comments There are not enough reports about pain management for vascular embolization using NBCA; however, it can be managed with close observation alone in most cases (64, 68) . When solid organs, such as the liver or kidneys are embolized, pain management might be necessary because it can result in acute pain. Previous reports have described the intravenous administration of pethidine and fentanyl after vascular embolization [77, 145, 176, 177, 188] , and non-pyrazolone analgesics (paracetamol etc.) or NSAID have been administered for pain management during the postoperative period [16, 188] .
NBCA is almost always used under general anesthesia in pediatric or cerebrovascular cases [82, 133, 142] . Some case reports have described the use of pain control drugs during the perioperative period; however, there is insufficient information about the optimal doses of pain control drugs (Table 6) . Organ ischemia or patient-specific factors might be responsible for the pain experienced in some cases. Since the polymerization of NBCA involves an exothermic reaction, it can result in the destruction of the vessel wall and the perivascular tissue [39, 64, 126] . It also causes pain; however, the mechanism responsible for this is unknown.
Special aspects of vascular embolization using NBCA CQ6 Is NBCA effective for patients in a coagulopathic state?
Recommendation NBCA is an effective embolic material for treating patients in a coagulopathic state because its polymerization, which is required for vessel occlusion, does not depend on biogenic coagulants.
Specific comments Gelatin sponge particles or metallic coils require biogenic coagulants in order to occlude vessels. By contrast, NBCA occludes vessels instantly by polymerizing in the blood, and hence, does not depend on biogenic coagulants. Therefore, it is considered that NBCA is more useful than other embolic materials, particularly in the setting of acute arterial hemorrhaging in coagulopathic conditions. However, it should be noted that NBCA has only been demonstrated to be useful in coagulopathic conditions in limited studies.
NBCA has been reported to be useful for clinical cases involving acute arterial hemorrhaging in coagulopathic conditions, as outlined below. In seven patients with acute lower gastrointestinal hemorrhaging and coagulopathy (elevated international normalized ratio [INR] : ]1.5), the technical success rate of vascular embolization using NBCA was 100 % [54] . In another report, vascular embolization with gelatin sponge for perinatal hemorrhaging in coagulopathic patients was not successful (INR = 1.55), but vascular embolization using NBCA was successful [66] . Furthermore, 18 coagulopathic (INR [ 1.5 or platelet count \ 80000/lL) patients who had undergone failed endoscopic embolization for non-variceal upper gastrointestinal bleeding subsequently underwent transcatheter arterial embolization with NBCA, and the clinical success rate of the procedure was 83 % (15/18) [72] . Vascular embolization using NBCA was also demonstrated to be effective for postoperative bleeding in hemophiliacs who underwent radical prostatectomy [75] . In addition, angiographic and clinical success were achieved in four patients who had underlying coagulopathy (INR [ 1.5 or platelet count \ 80000/lL) at the time of vascular embolization using NBCA for arterial esophageal bleeding [135] . In a case-control study of acute arterial hemorrhaging, 63 arteries in 46 patients with coagulopathy (INR [1.5 or platelet count \50000/lL) were embolized with gelatin sponge particles, fibered microcoils, or NBCA. The primary hemostatic rate was significantly higher in the NBCA group (16/16, 100 %) than in the gelatin sponge particle group (18/27, 67 %). In addition, the operations were completed more quickly in the NBCA group (9 min ± 4) than in the microcoils group (37 min ± 19) or the gelatin sponge particle group (25 min ± 10) [185] . In a swine model-based experimental study comparing the hemostatic durability achieved by NBCA and gelatin sponge particles during transcatheter arterial embolization for acute arterial hemorrhaging in coagulopathic conditions (activated clotting time [ 400 s), follow-up angiography performed after the embolization procedure detected recurrent hemorrhaging in four (80 %) of the five hemorrhages that had been embolized with gelatin sponge particles, but only one (20 %) of the five hemorrhages that were embolized with NBCA [186] .
Based on these findings, which admittedly only represent limited evidence, vascular embolization using NBCA results in greater hemostatic durability than gelatin sponge particle-based treatment, and vascular embolization can be completed most quickly using NBCA in cases of acute arterial hemorrhaging in coagulopathic conditions (e.g., INR[1.5 or platelet count\50000/lL). NBCA should be used as soon as possible to induce primary hemostasis in order to save the patient's life by preventing them from falling into an irrecoverable condition, especially in cases of life-threatening hemorrhagic shock involving severe traumatic injury or massive gastrointestinal bleeding.
CQ7 What types of contrast media can be mixed with NBCA?
Recommendation NBCA is mixed with contrast medium prior to its intravascular administration, because it is not visible under X-ray fluoroscopy [112] . Lipiodol or another oily contrast medium is usually used for this purpose (recommendation grade C1).
Lipiodol is an oily contrast medium. Its generic name is ethyl ester of iodinated poppy-seed oil fatty acids. In Japan, it has been used during hysterosalpingography and lymphangiography. When NBCA is mixed with Lipiodol, the NBCA becomes radiopaque, and its polymerization time is increased [119, 131, 168, 182] . The intravascular administration of Lipiodol is not approved for use by the Japanese pharmaceutical law or in any other country except France. The Lipiodol:NBCA mixing ratio is discussed in CQ8.
(2) Pantopaque Pantopaque (generic name: iophendylate) is another type of oily contrast medium. It has been used clinically from the 1940s, but is not currently available in Japan. It has similar characteristics to Lipiodol, and its radiopacity and its effect on the prolongation of the NBCA polymerization period are the same as those of Lipiodol [154] .
(3) Tantalum powder Tantalum powder is a rare metal powder. Tantalum has an atomic number of 73 and is referred to using the chemical symbol Ta. Tantalum powder is used to improve the visibility of NBCA, and 0.5-1.5 g/ml of the powder are used during vascular embolization using NBCA [10, 12, 20, 82, 96, 97, 143] . NBCA and ethylene vinyl alcohol (EVAL) products containing tantalum powder are available in foreign countries.
(4) Tungsten powder
Tungsten powder is another rare metal powder. Tungsten has an atomic of 74 and is referred to using the chemical symbol W. Tungsten powder is also used to improve the visibility of NBCA; however, it is cheaper than tantalum powder. Tungsten powder reduces the pH of NBCA-Lipiodol mixtures and prolongs their polymerization because of its strong acidity [147] . It behaves similarly to glacial acetic acid, which is mentioned in CQ8 [156] . There have been fewer studies about tungsten powder than about tantalum powder, and its use in clinical practice is fairly limited.
CQ8 Do operators need to change the NBCA-Lipiodol mixing ratio depending on the situation? Recommendation It is necessary to adjust the NBCA-Lipiodol mixing ratio depending on the situation. Operators should decrease the amount of Lipiodol when attempting to embolize short segments, and should increase it when attempting to embolize long segments (recommendation grade C1).
Specific comments NBCA is mixed with contrast materials such as Lipiodol before being used for vascular embolization because of its poor visibility under X-ray fluoroscopy. In addition to increasing the visibility of NBCA, changing the NBCALipiodol mixing ratio also affects the polymerization time [69, 122, 124, 148, 154] . A short polymerization time, i.e., using a small amount of Lipiodol, is suitable for occluding short blood vessel segments. After coming into contact with plasma, NBCA is completely polymerized within 0.087 s [132] . When the amount of Lipiodol is increased, NBCA polymerization is delayed because the NBCA is prevented from coming into contact with the blood, and the mixture travels further from the catheter tip, allowing longer vessel segments to be occluded. In vitro experiments examining the relationship between the NBCA-Lipiodol dose ratio and polymerization time have found that NBCALipiodol dose ratios of 1:1, 1:2, and 1:3 resulted in polymerization times of 3.2, 4.7, and 7.5 s, respectively (Table 7) .
A high NBCA concentration (more than 50 %) is used for embolizing cerebral AVM because such concentrations allow short vessel segments to be occluded without the NBCA flowing out from the nidus [10, 14, 26, 27, 46, 47, 96, 125] . In addition, high concentrations of NBCA are used for dilated vessels such as varicose veins to reduce the risk of NBCA migration [27] . However, it is necessary to appropriately adjust the concentration of Lipiodol according to the diameter of the target vessel, blood flow velocity, and the distance from the catheter tip to the lesion [11, 61, 96, 166] . NBCA concentrations of \ 50 % are often used in other IR procedures, whereas NBCA concentrations of 12.5-25 % are used to occlude entire arteries during bronchial artery embolization. Moreover, a low concentration of NBCA is used to occlude collateral arteries, e.g., to occlude the inferior phrenic artery during arterial infusion chemotherapy for liver cancer or to occlude the internal mammary artery during arterial infusion chemotherapy for advanced breast cancer [16, 180, 189] .
Glacial acetic acid is not used much in clinical practice; however, it can extend the polymerization time of NBCA because it reduces the pH of NBCA mixtures [93] .
CQ9 Is the use of combinations of NBCA and other embolic materials effective?
Recommendation Since it is a liquid, NBCA is different from metallic coils, gelatin sponge particles, and other embolic materials, and the complementary use of combinations of embolic materials can be effective. NBCA should be used by, or under the supervision of, experienced interventional radiologists, and it should always be remembered that the installation of other embolic materials can markedly affect Parentheses show NBCA volume: Lipiodol volume blood flow through the target vessel (recommendation grade C1).
Specific statement
Almost all kinds of embolic materials, including embolic devices such as metallic coils, vascular plugs, or detachable balloons; embolic particles such as gelatin sponges and polyvinyl alcohol; and embolic liquids such as EVAL can be used in combination with NBCA. The combined use of NBCA and other embolic materials has the advantage of preventing excessive embolization and shortening the procedure time [72, 120, 151, 171, 179] .
In the cerebrovascular field, vascular embolization is mainly used to treat patients with intracranial AVM, dural arteriovenous fistulas, and traumatic carotid-cavernous fistulas. In previous papers, several embolic devices were deployed in the proximal [10, 102, 105] or distal vessels [79, 101] of the target lesion to reduce blood flow through the lesion and prevent the injected NBCA from migrating. In addition, other studies have described various combination methods in which the target lesion was embolized with NBCA through the main feeding artery after embolic devices such as metallic coils had been deployed in numerous small feeding arteries or draining veins, or in which multiple tiny feeding arteries were occluded with particles after the majority of the target lesion had been embolized with NBCA [20, 58, 81, 128] .
In the thoracoabdominal field, embolic devices are often deployed in the distal portion of the target lesion to prevent the distal migration of NBCA [19, 34, 72, 108, 109, 149, 163] , and NBCA is sometimes used in combination with other embolic materials in cases in which the target lesion was insufficiently embolized [72, 77, 81, 87, 134, 162, 180, 182] . NBCA has also been occasionally used to fix the tips of indwelling catheters in place during hepatic arterial infusion chemotherapy [173, 181] . Operators should keep in mind that the blood flow of the target vessel can change dramatically after or during the use of other embolic materials.
In particular, it is essential to pay attention to unexpected complications, including cast spillover or migration and non-target embolization due to collateral circulation. Therefore, NBCA should be used by, or with the assistance of, proficient doctors.
Conclusion
Vascular embolization using NBCA is effective at stopping hemorrhaging and controlling vascular disease and tumors, although the use of NBCA for vascular embolization is an off-label treatment in Japan. Interventional radiologists should have a detailed knowledge of the indications for, and complications associated with, NBCA use before employing it in clinical practice.
